

Resource Summary Report

Generated by NIF on Jul 30, 2026

VCL (vinculin) Antibody (against the C terminal of VCL)(50ug)

RRID:AB_10872742

Type: Antibody

Proper Citation

Aviva Systems Biology Cat# ARP61099_P050, RRID:AB_10872742

Antibody Information

URL: http://antibodyregistry.org/AB_10872742

Proper Citation: Aviva Systems Biology Cat# ARP61099_P050, RRID:AB_10872742

Target Antigen: VCL (vinculin) (against the C terminal of VCL)(50ug)

Host Organism: rabbit

Clonality: polyclonal

Comments: functionality unknown, check validation data for this product with vendor

Antibody Name: VCL (vinculin) Antibody (against the C terminal of VCL)(50ug)

Description: This polyclonal targets VCL (vinculin) (against the C terminal of VCL)(50ug)

Target Organism: human

Antibody ID: AB_10872742

Vendor: Aviva Systems Biology

Catalog Number: ARP61099_P050

Record Creation Time: 20250819T223129+0000

Record Last Update: 20250820T022743+0000

Ratings and Alerts

No rating or validation information has been found for VCL (vinculin) Antibody (against the C terminal of VCL)(50ug).

No alerts have been found for VCL (vinculin) Antibody (against the C terminal of VCL)(50ug).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Gurska LM, et al. (2023) Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(5), 943.